GSK signs $1 billion siRNA partnership with China's SiranBio to target obesity
read at Endpoints ↗DealPositive
GSK is expanding its cardiometabolic portfolio by entering a new collaboration with Chinese biotech SiranBio.
The agreement is valued at $1 billion in biobucks and focuses on developing siRNA therapeutics aimed at obesity, leveraging Arrowhead's platform.
The deal deepens GSK's engagement with Chinese biotech firms and signals continued interest in RNA-based treatments for metabolic diseases.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane”
read at Endpoints ↗87 words · retrieved May 6
comments(0)
5-min edit window · permanent after that